Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
February 04 2021 - 7:05AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that it will
host a conference call and webcast for investors and analysts on
Thursday, February 18, 2021 at 11:00am ET to discuss GB004, its
oral HIF-1α stabilizer for the treatment of inflammatory bowel
disease (IBD), including ulcerative colitis (UC).
Gossamer management will present alongside key IBD and HIF
biology opinion leaders, including:
- William Sandborn, M.D., Director of the Inflammatory Bowel
Disease Center and Chief of the Division of Gastroenterology at UC
San Diego Health
- Silvio Danese, M.D., Ph.D., Unit Director of the Inflammatory
Bowel Disease Clinical and Research Unit at Humanitas Research
Hospital, Milan, Italy
- Cormac Taylor, Ph.D., Professor of Cellular Physiology at
University College Dublin
As part of the event, Gossamer Bio management and Drs. Sandborn,
Danese, and Taylor will be available for questions.
William Sandborn, M.D., is a board-certified
gastroenterologist, who is one of the world's top experts in the
management of ulcerative colitis and Crohn’s disease. He directs
the Inflammatory Bowel Disease Center at UC San Diego Health. In
addition, he is Chief of the Division of Gastroenterology for UC
San Diego Health. A Professor in the Department of Medicine at UC
San Diego School of Medicine, Dr. Sandborn conducts clinical trials
in IBD and leads a team of physicians, research fellows, nurses,
and study coordinators. His clinical trials have been instrumental
to developing modern treatments for IBD. Dr. Sandborn has published
836 articles in prestigious journals, including the New England
Journal of Medicine, The Lancet, JAMA, the Annals of Internal
Medicine, and Gastroenterology. Prior to joining UC San Diego
Health, Dr. Sandborn worked in the Division of Gastroenterology and
Hepatology at the Mayo Clinic in Rochester, Minnesota. Dr. Sandborn
completed his fellowship at Mayo Clinic. He did his residency and
earned his medical degree at Loma Linda University School of
Medicine.
Silvio Danese, M.D., Ph.D., is the Head of the
Inflammatory Bowel Disease Center at Humanitas Research Hospital
and the group leader of the Gastrointestinal Immunopathology
Laboratory at Humanitas Research Center in Milan, Italy. A
Professor of Gastroenterology at Humanitas University, his main
research area of interest is the investigation of the fundamental
mechanisms underlying IBD pathogenesis. He served as President of
the European Crohn’s and Colitis Organization (ECCO) in 2019 and
has served as the Principal Investigator on many Phase 1, 2 and 3
clinical trials for the treatment of IBD patients. He is also
Member of the Editorial Board of Current Drug Target and Alimentary
Pharmacology & Therapeutics and Associate Editor of Gut and
Journal of Crohn’s and Colitis. He has published more than 300
research articles in peer-reviewed journals with high impact
factor. He trained in gastroenterology at Policlinico Gemelli,
Rome, Italy, and earned his Ph.D. there in 2004. Professor Danese
also worked in Professor Claudio Fiocchi’s laboratory at the Case
Western Reserve University, Cleveland, Ohio from 2001 to 2004.
Cormac Taylor, Ph.D., is a Professor of Cellular
Physiology at the School of Medicine and Medical Science and the
Conway Institute, University College Dublin, Ireland. He leads the
Taylor Lab, in which research is directed towards expanding the
understanding of the physiological and pathophysiological
mechanisms by which changes in micro-environmental oxygen levels
regulate gene transcription in cells. A key focus of this work is
the identification of new therapeutic targets in inflammatory bowel
disease. Dr. Taylor was elected as a Member of the Royal Irish
Academy in 2014. He was awarded the 2014 Nature mid-career
mentorship award and the 2017 Takeda Distinguished Researcher Award
from the American Physiological Society. He has authored over 130
articles in journals including Gastroenterology, Gut, PNAS and
Science and is an Editorial Board Member of the American Journal of
Physiology and the Journal of Biological Chemistry. Dr. Taylor
received his Ph.D. in Pharmacology from UCD in 1996 prior to a
postdoctoral fellowship at Harvard Medical school from 1996-2001
and has been running his own independent research group since
2001.
Conference Call and Webcast
Gossamer will host a conference call and live audio webcast at
11:00 am ET on Thursday, February 18. The live audio webcast may be
accessed through the “Events / Presentations” page in the
“Investors” section of the Company's website at
www.gossamerbio.com. Alternatively, the conference call may be
accessed through the following:
Conference ID: 6135079 Domestic Dial-in Number:
(833) 640-7726 International Dial-in Number: (602) 585-9912
Live Webcast:
https://edge.media-server.com/mmc/p/9tbs35gb
A replay of the audio webcast will be available for 30 days on
the “Investors” section of the Company's website,
www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210204005067/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024